CHICAGO ― Lesser survival seen in elderly men with diffuse large B-cell lymphoma (DLBCL) than in elderly women in response to standard therapy appears to be due to sex-related differences in the clearance rates of rituximab (Rituxan, Genentech/Roche) and could be improved by increasing the dose in older men, investigators reported at the 2014 Annual Meeting of the American Society of Clinical Oncology.

READ FULL ARTICLE Curated publisher From Med Scape